INTRODUCTION
Despite advances in T-cell leukemia therapy, only a minority of patients achieves long term tumor-free survival with conventional chemotherapy at the cost of significant and often irreversible toxic side effects [1] Therefore, new therapeutic approaches with enhanced tumor selectivity and more favorable toxicity profiles are urgently needed.
Several promising targeted approaches have been developed, including naked antibodies [2;3], immunotoxins [4;5] and various cancer-selective small inhibitory molecules [6;7] .
Furthermore, certain members of the tumor necrosis factor (TNF) superfamily show promising proapoptotic activity toward various human leukemias and lymphomas.
Fas ligand (FasL), a prominent member of the TNF superfamily, shows superior antileukemia activity. FasL is present on lymphocytes and monocytes/macrophages as a type II transmembrane protein, (memFasL). Fas, the cognate receptor for FasL, belongs to the family of transmembrane proteins known as death receptors. Death receptors can detect the presence of specific extracellular death signals and rapidly trigger cellular destruction by apoptosis. Fas expression at the cell surface is observed in biopsies and cell lines derived from a variety of tumors. Moreover, the antitumoral effects of various chemotherapeutic drugs have been attributed partly to p53-mediated up-regulation of Fas signaling is also known to be a key element in the effector phase of a cytotoxic T lymphocyte (CTL) response against tumor cells.
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Like other members of the TNF superfamily, the extracellular domain of FasL can be proteolytically cleaved into a soluble homotrimeric form (sFasL) [13] [14] [15] .
Early attempts to exploit Fas agonists such as anti-Fas antibodies and multimeric recombinant FasL preparations for therapy revealed extremely potent tumoricidal effects toward isolated primary tumor cells and cell lines [15] [16] [17] [18] [19] . However, in vivo application of most Fas antagonists was associated with acute lethality in mice [20] [21] [22] , thereby excluding therapeutic evaluation in humans. Nevertheless, the principal feasibility of therapeutic Fas activation in cancer therapy was clearly demonstrated in mice that lack a functional FasL/Fas system (lpr/gld mice) [23] and by treatment of xenografted tumors with human Fas-specific antibodies [24] .
Recent studies have revealed that certain recombinant FasL preparations contain oligomeric, multimeric, and even aggregated sFasL forms and that these forms are responsible for the observed systemic toxicity [25] . In contrast, homotrimeric sFasL is not toxic to normal cells and may even antagonize the function of membrane-bound FasL [25] [26] [27] . Importantly, homotrimeric sFasL also lacks tumoricidal activity. However, selective delivery of sFasL to a predetermined tumor-associated target antigen can restore the full apoptotic potential of sFasL [28] .
Recently, we demonstrated that the leukemia selectivity of homotrimeric TRAIL (TNFrelated apoptosis-inducing ligand), another TNF superfamily member, can be strongly enhanced by genetically fusing it to a CD7-selective antibody fragment [29] . Human CD7 is a lineage-specific antigen that is highly expressed in patients with acute T-cell leukemia and in approximately 10% of patients with acute myeloid leukemia [30] [31] [32] [33] . The function of CD7 is not yet fully understood. In normal cells CD7 expression is limited to T and myeloid cells in early hematopoietic-cell ontogeny, thymocytes, natural killer (NK) cells, and to a distinct subset of peripheral-blood T cells [34] [35] [36] [37] [38] . Human CD7 has been used for the targeted delivery of several monoclonal antibody (mAb) toxin conjugates in both preclinical studies and clinical trials [4;5;39;40] .
Here, we report on a novel homotrimeric sFasL fusion protein, designated scFvCD7:sFasL, with enhanced and leukemia-restricted activity toward T-cell acute lymphoblastic leukemia (T-ALL) cell lines and patient-derived T-ALL, peripheral T-cell lymphoma (PTCL), and CD7-positive acute myeloid lymphoma (AML) cancer cells. We provide evidence that homotrimeric scFvCD7:sFasL is bioactive only after specific binding to cell-surfaceexpressed CD7 with no toxicity toward CD7-negative cells and only moderate activity toward interleukin-2 (IL-2)/CD3-activated CD7-positive T cells.
MATERIAL AND METHODS
mAbs and scFv antibody fragment mAb TH69 is a murine immunoglobulin G1 (IgG1) with specificity for human CD7 [3] (kindly provided by Dr Martin Gramatzki, University Clinic Schleswig-Holstein, Kiel, Germany). Phagemid pCANTAB5E/scFv3A1F encoding anti-CD7 antibody fragment 3A1F
[41] was kindly provided by Dr Chris Pennell (Department of Laboratory Medicine and Pathology, University of Minnesota). mAb TH69 and scFv3A1F compete for binding to the extracellular domain of human CD7. FasL-neutralizing mAb Alf2.1 was purchased from Sigma-Aldrich Chemie (Zwijndrecht, the Netherlands). Flag-tagged sFasL was purchased 22 CHAPTER 2 from Alexis (10P's BVBA; Breda, the Netherlands). Flag-tagged sFasL was secondarily cross-linked by preincubation with 5-fold excess of anti-Flag mAb M2 (Alexis).
Chemotherapeutics
The cytostatic drugs used are vincristine (stock; 1mg/mL in phosphate-buffered saline
[PBS]), amsacrine (stock; 1 mM in PBS), and actinomycin D (stock; 2mg/mL in ethanol).
Farnesyl transferase inhibitor L-744832 (Merck, Darmstadt, Germany) was dissolved at 10mM in DMSO. The proteasome inhibitor bortezomib was dissolved at 10mM in dH2O. All final concentrations were prepared by serial dilutions in serum-free medium.
Cell lines
Human CD7-positive T-ALL cell lines Jurkat, CEM, and the CD7-negative human B-cell lymphoma cell lines Ramos and Raji were purchased from the American Type Culture Collection (ATCC; Manassas, VA). T-cell lines MOLT16 and HuT78 were a kind gift from Dr Martin Gramatzki. A CD7-positive transfectant of the Ramos cell line (Ramos.CD7) was generated previously [29] . All cell lines were cultured in RPMI (Cambrex, East Rutherford, NJ) supplemented with 10% fetal calf serum (FCS) at 37°C in a humidified 5% CO2 atmosphere.
Leukocytes, PBLs, activated T cells, and HUVECs
Leukocytes were isolated from whole blood of healthy donors by standard Ammonium Chloride method [42] . Peripheral-blood lymphocytes (PBLs) were isolated from whole blood of healthy donors by standard density gradient centrifugation procedures (Lymphoprep; Axis-Shield PoC As, Oslo, Norway). Freshly isolated PBLs were resuspended at 2.0 x 10 6 cells/ml in RPMI, supplemented with 10% human pooled serum. Activated T cells were generated by incubation of freshly isolated PBLs with anti-CD3 mAb WT32 (0.5µg/mL) for 72 hours, followed by IL-2 stimulation (100ng/mL) for 48 hours. Human umbilical vein endothelial cells (HUVECs) were isolated as previously described [43] . HUVECs were used before culture passage no. 4 and, for experiments, were pre-cultured in 6-well plates at 60% confluency.
Construction of scFvCD7:sFasL
Previously, we constructed the eukaryotic expression plasmid pEE14scFv:sTRAIL for rapid construction, evaluation, and stable expression of scFv:sTRAIL fusion proteins in CHO-K1 cells [44] . Important features of this vector are the murine kappa light-chain leader peptide encoded upstream of 2 multiple cloning sites (MCSs) that are separated by a 26-residue in-frame linker sequence, and the glutamine synthetase selectable marker gene, which allows for amplified expression of the recombinant protein in the established industrial production cell line CHO-K1. The vector exploits the strong cytomegalovirus (CMV) promoter to drive recombinant protein expression, while the leader peptide directs secretion of the recombinant protein into the culture supernatant. In the first MCS, a 745-bp DNA fragment encoding anti-CD7 scFv3A1F derived from Phagemid pCANTAB5E/ scFv3A1F was directionally inserted using the unique SfiI and NotI restriction enzyme 
Production of scFvCD7:sFasL
ScFvCD7:sFasL was expressed in CHO-K1 cells using the glutamine synthetase selection/ amplification system essentially as described previously [44] . Briefly, CHO-K1 cells were transfected with pEE14scFvCD7: sFasL using FuGENE-6 reagent (Roche Diagnostics, Almere, the Netherlands). Stable transfectants with amplified expression were isolated and single-cell-sorted by high-speed cell sorter (Cytomation, Ft Collins, CO). Individual clones were assessed for stable and high secretion of scFvCD7: sFasL in the absence of MSx selection reagent by FasL enzyme-linked immunosorbent assay (ELISA) according to manufacturer's recommendations (Axora, San Diego, CA). This procedure identified CHO-K1 production cell line 100B2, stably secreting scFvCD7:sFasL (1.34 µg/mL) into the medium. ScFvCD7:sFasL containing supernatant was harvested (10.000g for 10 minutes) and stored at -80°C.
Solution behavior of scFvCD7:sFasL
The solution behavior of scFvCD7:sFasL was analyzed by size-exclusion (SE) fastperformance liquid chromatography (FPLC) with a calibrated HiLoad 16/60 Superdex 200 Prep-grade column (Amersham Biosciences, Uppsala, Sweden); 5 mL supernatant derived from CHO-K1 cell line 100B2 was loaded onto the column, after which individual samples were collected at a 3-minute interval. Individual samples were analyzed for their capacity to induce apoptosis in CD7-positive FasL-sensitive MOLT16 cells.
CD7-specific binding of scFvCD7:sFasL
CD7-specific binding of scFvCD7:sFasL was analyzed by incubating 1.0 x 10 6 CEM cells with scFvCD7:sFasL (1.34µg/mL) in the presence or absence of CD7-blocking mAb TH69
(5µg/mL). CD7-specific binding was analyzed by flow cytometry with PE-conjugated antiFasL mAb (Diaclone SAS, Besancon, France). Incubations were performed for 45 minutes at 0°C and were followed by 2 washes with serum-free medium.
CD7-restricted induction of apoptosis by scFvCD7:sFasL
Tumor cells were seeded at 0.25 x 10 6 cells/well in a 48-well plate and treated for 16 hours with the indicated concentrations of scFvCD7:sFasL in the presence or absence of mAb TH69 (5µg/mL) or mAb Alf2.1 (1µg/mL). Where indicated, cells were treated with crosslinked sFasL (Flag-tagged sFasL) or with scFvCD7:sTRAIL [29] . Apoptosis was assessed by one of the assays described in "Assays used to assess apoptosis." Percentage of specific apoptosis was calculated using the following formula: specific apoptosis = (experimental apoptosis -spontaneous apoptosis)/(100 -spontaneous apoptosis) x 100%. 
Differential quantification of apoptosis in target and bystander cells in mixed-culture experiments
For mixed-culture experiments, CD7-positive target cells were labeled with the red fluorescent dye DiI (Molecular Probes). Briefly, cells (1.0 x 10 6 cells/mL) were incubated for 5 minutes at 37°C in serum-free medium containing 5µM DiI, followed by 3 washes with standard medium. DiI-labeled target and non-labeled bystander cells were mixed at indicated ratios with a final cell concentration of 0.5 x 10 6 cells/well in a 48-well plate.
After treatment, differential fluorescent characteristics of target cells and bystander cells were used to separately evaluate apoptosis by PS exposure to the outer cell membrane or by Δψ.
Additive induction of apoptosis by scFvCD7:sFasL, chemotherapeutics, and small inhibitory molecules
Additive apoptotic effects of treatment of cells with scFvCD7:sFasL and various chemotherapeutics or small inhibitory molecules was determined using the cooperativity index (CI), in which the sum of apoptosis induced by single-agent treatment is divided by apoptosis induced by combination treatment. When CI was less than 1, treatment was considered synergistic; when CI equaled 1, treatment was considered additive; and when CI was greater than 1, treatment was considered antagonistic.
CD7-restricted induction of apoptosis in patient-derived leukemic cells
Blood cells derived from 4 individual patients with T-ALL (patient nos. 1 to 4), 1 patient with PTCL (patient no. 5), and 1 patient with CD7-positive AML (patient no. 6) were treated for 16 hours with scFvCD7:sFasL (150ng/mL) in the presence or absence of mAb TH69 where indicated. In addition, blood cells derived from patient no. 6 (AML) were cotreated with either vincristine or amsacrine. Apoptosis was assessed by PS exposure to the outer cell membrane and staining for active caspase-3 as described. 
CD7-restricted induction of apoptosis by homotrimeric scFvCD7:sFasL
Incubation of CEM cells with homotrimeric scFvCD7:sFasL resulted in strong and specific binding to the cell surface ( Figure 2A , solid line), which was inhibited by pre-incubation with mAb TH69 ( 
RESULTS

Fractionation and stability of homotrimeric scFvCD7:sFasL
Fractionation of crude supernatant containing scFvCD7:sFasL by SE-FPLC and subsequent assessment of the apoptotic activity of each separate fraction revealed 2 peaks of apoptotic activity of 160 kDa and 700 kDa, respectively ( Figure 1A) . The peak corresponding to a molecular weight (MW) of approximately 160 kDa closely resembles that of the calculated MW of 147 kDa for homotrimeric scFvCD7:sFasL. Samples taken from this peak showed strong and CD7-restricted induction of apoptosis toward MOLT16 cells, which was completely abrogated by pretreatment with CD7-blocking mAb TH69.
Samples taken from the 700-kDa peak showed strong apoptosis induction toward both CD7-positive MOLT16 cells and CD7-negative Ramos cells, which in contrast to the 160 kDa peak could not be inhibited by pretreatment with mAb TH69. Fractions from the 700-kDa peak were discarded. Fractions from the 160 kDa peak containing homotrimeric scFvCD7:sFasL were pooled and used for further experimental procedures and analyses.
Subsequently, we analyzed for secondary formation of scFvCD7:sFasL multimers or aggregates. Prolonged storage of up to 7 days at 37°C in medium containing 15% serum did not lead to any detectable secondary formation of multimers or aggregates (data not shown). Furthermore, samples of scFvCD7:sFasL stored for up to 9 days at 37°C in the presence of serum retained potent and CD7-restricted apoptotic activity toward FasLsensitive MOLT16 cells ( Figure 1B) . CEM, Jurkat, In Ramos.CD7 target cells, scFvCD7:sFasL potently induced apoptosis ( Figure 3A) . In addition, in Raji bystander cells, a bystander apoptotic effect of up to 34% was detected ( Figure 3B ). In both target and bystander cells, apoptosis was specifically inhibited in the presence of mAb TH69 or mAb Alf2.1 (Figure 3A-B) . No bystander apoptosis was observed when parental CD7-negative Ramos cells were used in this experiment (data not shown). 
Absence of apoptotic activity of homotrimeric scFvCD7:sFasL toward PBLs and leukocytes
A subpopulation of normal PBLs is CD7-positive and might sustain collateral damage during treatment. Therefore, we investigated the apoptotic activity of homotrimeric scFvCD7:sFasL toward normal PBLs. To this end, PBLs were treated with excess amounts of scFvCD7:sFasL (325ng/mL) for up to 7 days, which revealed no specific induction of apoptosis. In contrast, treatment with cross-linked sFasL (100ng/mL) did result in increasing amounts of apoptosis in time ( Figure 4A ). Next, we assessed a Figure 4B ; PBLs, 8%; Jurkat, 72%). Again, cross-linked sFasL did induce apoptosis in both Jurkat and PBLs ( Figure 4B ; PBLs, 23%; Jurkat, 70%).
Figure 4. Treatment of normal human leukocytes, activated T cells, and HUVECs with scFvCD7:sFasL. (A) Resting PBLs were subjected to treatment with scFvCD7:sFasL (325ng/mL), or crosslinked sFasL (100ng/mL) for up to 7 days, after which experimental apoptosis was assessed by annexin V/PI staining. Indicated values are representatives of 3 independent experiments. (B) Isolated PBLs were mixed at a ratio of 1:10 with DiI-labeled Jurkat cells. Mixed cultures were treated for 24 hours with scFvCD7:sFasL (100 ng/mL) or secondarily cross-linked sFasL (100ng/mL). Differential fluorescent labeling of Jurkat target cell and PBLs was used to separately evaluate apoptosis induction by annexinV staining. Indicated values are representatives of 3 independent experiments. (C) Activated T cells were subjected to treatment with scFvCD7:sFasL (325ng/mL) for up to 7 days, after which apoptosis was assessed by annexinV/PI staining. Indicated values are representatives of 3 independent experiments. (D) Resting HUVECs were treated for 24 hours with scFvCD7:sFasL (100ng/mL), secondarily cross-linked sFasL (100ng/mL), or actinomycin D (2µg/mL). Apoptosis was assessed by Δψ. (E) Resting HUVECs were mixed with fluorescently labeled Jurkat cells (ratio 1:1) and treated with scFvCD7:sFasL (100ng/mL) or actinomycin D (2µg/ml) for 24 hours. Differential fluorescent labeling of Jurkat target cells and HUVEC bystander cells was used to separately evaluate apoptosis by
Moderate apoptotic activity of homotrimeric scFvCD7:sFasL toward activated T cells
Treatment of anti-CD3/IL-2 activated T cells with excess amounts of homotrimeric scFvCD7:sFasL(325 ng/mL) induced apoptosis in approximately 45% of activated T cells at day 1 ( Figure 4C ). Up to day 7, scFvCD7:sFasL consistently induced apoptosis of approximately 15% in these cells.
No apoptotic activity toward resting HUVECs
To simulate the effect of scFvCD7:sFasL on human endothelial cells, HUVECs were treated with excess amounts of homotrimeric scFvCD7:sFasL. No apoptosis was detected after 24 hours of treatment with homotrimeric scFvCD7:sFasL ( Figure 4D ; 2%), whereas treatment with cross-linked sFasL or actinomycin D significantly induced apoptosis ( Figure 4D ; 7% and 53%, respectively). After treatment, cells from patient no. 4 were analyzed for the formation of active caspase-3. Specific staining indicated the activation of caspase-3 in more than 20% of the tumor cells, whereas untreated cells showed no formation of active caspase-3 ( Figure   7C ).
Additive apoptotic effect of treatment of primary leukemic cells with scFvCD7:sFasL and chemotherapeutic agents
Blood samples derived from patient no. 6 (CD7-positive AML) were treated simultaneously with scFvCD7:sFasL and either vincristine (1ng/mL) or amsacrine (1µM) ( Figure 7D) . In both cases, combination treatment resulted in an additive induction of apoptosis ( Figure  7D ; CI=1.0).
DISCUSSION
Agonistic anti-Fas antibodies and multimeric recombinant FasL preparations show highly potent antileukemia activity. However, attempts to exploit these conventional Fas agonists for cancer therapy have met with unacceptable systemic toxicity, largely excluding Fas signaling as a therapeutic strategy for treatment of human malignancies.
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The toxicity observed for sFasL preparations appears to be directly related to the presence of multimeric and aggregated sFasL species that are frequently formed during or after overexpression in primitive host cells such as Escherichia coli. Moreover, it was shown that as few as 2 adjacent trimeric (hexameric) sFasL molecules are already sufficient for Fas signaling in Raji, Jurkat, and activated T cells, as was evidenced by the formation of a death-inducing signaling complex (DISC) and subsequent apoptosis induction [47].
We produced scFvCD7:sFasL in Chinese hamster ovary (CHO) cells, a currently favored industrial host-cell type for production of therapeutic recombinant proteins. We used a murine kappa light-chain leader peptide to direct produced scFvCD7: sFasL through the endoplasmic reticulum (ER) and Golgi complex, thus taking advantage of the associated stringent quality control mechanisms that facilitates secretion of correctly folded and non-aggregated scFvCD7:sFasL into the culture medium. Using SE chromatography we removed most, if not all, unwanted multimeric forms of scFvCD7:sFasL. Importantly, prolonged storage of homotrimeric scFvCD7:sFasL at 37°C in the presence of serum did not result in any detectable secondary aggregate formation, whereas apoptotic activity was retained. From this we conclude that scFvCD7:sFasL can be produced as soluble homogeneous homotrimers with no or only minimal secondary aggregate formation. these elegant experiments it cannot be concluded that in humans a similar favorable toxicity profile will be observed.
In the current study, we explored the feasibility and safety of scFv-targeted Specific apoptosis (%) P a t i e n t 1 P a t i e n t 2 P a t i e n t 3 P a t i e n t 4 P a t i e n t 5 P a t i e n t 6 Subsequently, the effect observed ex vivo may be an underestimation of the therapeutic effect of scFvCD7:sFasL when applied in vivo. In addition, a marked variability in response was observed between patient samples, which might be related to differences in CD7
T-ALL
or Fas expression or, alternatively, differential expression of intracellular modulators of apoptosis such as the caspase-8 homolog cFLIP.
Various chemotherapeutic agents are known to sensitize tumor cells to Fas-mediated apoptosis at distinct levels, including receptor-proximal, mitochondrial, and/or effectorcaspase level. We subjected blood samples derived from patient no. 6 (CD7-positive AML) to cotreatment with scFvCD7:sFasL and suboptimal concentrations of the chemotherapeutic agents vincristine and amsacrine that are already part of clinical practice. Cotreatment resulted in promising additive effects on apoptosis induction ( Figure 7D ). Importantly, identical treatment of normal PBLs, activated T cells, and resting/activated HUVECs did not result in significant increases in apoptosis compared with chemotherapy alone. In conclusion, we describe a novel and promising anti-T-cell leukemia agent that shows strong CD7-restricted tumoricidal activity toward various CD7-positive leukemia cell types that can be augmented with various chemotherapeutic agents and small inhibitory molecules 
